- Lexaria’s DIAB-A22-1 animal model study just concluded, highlighting three positive outcomes, including an improvement in general activity, significant reductions in body weight, and improved triglyceride and cholesterol levels
- The study was undertaken by a third-party testing laboratory in Canada involving 24 obese and eight lean rats for a total of 32 male Zucker rats
- The success of this DIAB-A22-1 study marks a significant milestone for Lexaria, even as it continues to explore its patented DehydraTECH(TM) technology application in various other areas, including nicotine replacement, epilepsy, hypertension, dementia and more
- With its unique product offering, a growing list of patents, and unique market positioning, Lexaria is becoming a key player in the drug delivery technology space
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the completion of its DIAB-A22-1 animal model study, which explored the potential of the patented DehydraTECH(TM)-processed CBD to treat diabetes. Of note were three positive outcomes, including an improvement in general activity, reductions in body weight, and better triglyceride and cholesterol levels.
The study, undertaken by a leading, third-party testing laboratory in Canada, administered select Lexaria “DehydraTECH-CBD 2.0” formulations with doses of either 30 mg/Kg or 100 mg/Kg of body weight. It involved 24 obese and eight lean rats for a total of 32 male Zucker (“ZDF”) rats. As Lexaria’s first study in…
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.